Skip to content
Menu

Silo Pharma, Inc. SILO

Full chart Compare
Set alert

Price alert · SILO

All alert types
1.88 USD -0.01 (-0.53%)

Regular-session close

1.85 -0.03 -1.60%

After hours · Nov 19, 4:00 PM ET

1.75 Day range 2.00
1.10 52-week range 10.43
YTD
-63.14%
1 year
-68.30%

5D -0.13 (-7.60%)

1.601.802TueWedThuFriMon1.58
Market cap
4.05M
Revenue (ttm)
72.10K
EPS (ttm)
-4.26
Shares out
4.48M
Forward P/E
-1.26
YTD return
-63.14%
1-year return
-68.30%
Volume
96.92K
Avg volume
64.80K
Open
1.89
Previous close
1.89
Day's range
1.75 – 2.00
52-week range
1.10 – 10.43
Beta
1.36

Key statistics

50-day average
1.04
200-day average
1.43
Enterprise value
-2.68M
Price / sales
54.94
Price / book
0.42
Free cash flow
-2.09M
Total cash
7.61M
Return on equity
-48.34%
Short % of float
2.37%

Fundamental scorecard

6 of 25 checks passed on SILO’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SILO Revenue — quarterly 0
SILO Net income — quarterly -358.74K
SILO EPS — quarterly -0.21

Earnings

SILO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 20240.00-0.22——
Aug 13, 2024Jun 1, 20240.00-0.31——
May 13, 2024Mar 1, 20240.00-0.28——

Upgrades / downgrades

SILO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 28, 2023Laidlaw & Co.init—Buy

About Silo Pharma, Inc.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SILO — it syncs with the Stock Master app.

Insider holders

SILO insider holders
InsiderRelationLatest transactionDateShares held
RYWECK DANIEL E.Chief Financial OfficerPurchaseMay 25, 20235,000
WEISBLUM ERICChief Executive OfficerPurchaseDec 12, 2024187,932

Institution ownership

SILO institution ownership
Holder% heldSharesValueReported
Renaissance Technologies, LLC0.23%227,006200.54KSep 29, 2024
Geode Capital Management, LLC0.03%30,76127.17KSep 29, 2024
Virtu Financial LLC0.03%25,61522.63KSep 29, 2024
Vanguard Group Inc0.02%16,33414.43KSep 29, 2024
Federation Des Caisses Desjardins Du Quebec0.01%6,0005.30KSep 29, 2024
State Street Corporation0.01%12,50011.04KSep 29, 2024

Fund ownership

SILO fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.02%16,33414.43KSep 29, 2024
Fidelity Extended Market Index Fund0.02%24,48021.63KOct 30, 2024
Fidelity Series Total Market Index Fund0.01%7,1206.29KOct 30, 2024
Fidelity Total Market Index Fund0.00%3,8963.44KOct 30, 2024